What is HC Wainwright’s Estimate for Zymeworks Q1 Earnings?

Zymeworks Inc. (NYSE:ZYME) – HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Zymeworks in a report issued on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.46). HC Wainwright has a “Neutral” rating and a $13.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.

Other research analysts also recently issued reports about the company. Citigroup raised their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target on the stock in a report on Monday, December 16th. Lifesci Capital initiated coverage on Zymeworks in a report on Tuesday. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Wells Fargo & Company lifted their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Zymeworks Stock Up 5.4 %

ZYME opened at $11.70 on Wednesday. The stock’s fifty day moving average is $14.01 and its two-hundred day moving average is $13.66. The company has a market capitalization of $814.05 million, a P/E ratio of -7.80 and a beta of 1.13. Zymeworks has a 52 week low of $7.97 and a 52 week high of $17.70.

Institutional Trading of Zymeworks

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new stake in Zymeworks during the 4th quarter worth about $527,000. Voloridge Investment Management LLC acquired a new stake in Zymeworks during the 4th quarter worth about $640,000. Point72 Asset Management L.P. lifted its position in Zymeworks by 565.8% during the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock worth $4,833,000 after acquiring an additional 280,544 shares during the period. Nuveen Asset Management LLC lifted its position in Zymeworks by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after acquiring an additional 886 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock valued at $22,645,000 after buying an additional 17,849 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Transactions at Zymeworks

In other Zymeworks news, CEO Kenneth Galbraith sold 57,291 shares of Zymeworks stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $854,781.72. Following the completion of the sale, the chief executive officer now owns 47,543 shares of the company’s stock, valued at approximately $709,341.56. The trade was a 54.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ecor1 Capital, Llc purchased 204,098 shares of the stock in a transaction on Friday, January 10th. The shares were purchased at an average cost of $13.13 per share, with a total value of $2,679,806.74. Following the transaction, the director now owns 15,411,078 shares in the company, valued at $202,347,454.14. This trade represents a 1.34 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 603,539 shares of company stock valued at $8,384,708 and sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.